Lineage to Present at B. Riley Securities 2022 Neuro & Ophthalmology Virtual Investor Conference on April 27, 2022
April 26 2022 - 8:00AM
Business Wire
Fireside Chat with B. Riley Research Analyst
Scheduled for 3:30pm Eastern Time
Topics Will Include Two New Cell Therapy
Programs Launched Following Roche and Genentech Partnership for
RG6501 (OpRegen®) Program
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX),
a clinical-stage biotechnology company developing allogeneic cell
therapies for unmet medical needs, announced today Brian M. Culley,
Lineage’s Chief Executive Officer, will present at the B. Riley
Securities 2022 Neuro & Ophthalmology Virtual Investor
Conference, in a fireside chat hosted by Mayank Mamtani, Managing
Director, Senior Biotech Research Analyst and Group Head of
Healthcare Research at B. Riley Securities, on Wednesday April
27th, 2022 at 3:30pm EST.
Interested parties can register to view both the live event and
replay on the Events and Presentations section of Lineage’s
website. Additional videos are available on the Media page of the
Lineage website.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology
company developing novel cell therapies for unmet medical needs.
Lineage’s programs are based on its robust proprietary cell-based
therapy platform and associated in-house development and
manufacturing capabilities. With this platform Lineage develops and
manufactures specialized, terminally differentiated human cells
from its pluripotent and progenitor cell starting materials. These
differentiated cells are developed to either replace or support
cells that are dysfunctional or absent due to degenerative disease
or traumatic injury or administered as a means of helping the body
mount an effective immune response to cancer. Lineage’s clinical
programs are in markets with billion dollar opportunities and
include five allogeneic (“off-the-shelf”) product candidates: (i)
OpRegen, a retinal pigment epithelium transplant therapy in Phase
1/2a development for the treatment of dry age-related macular
degeneration, which is now being developed under a worldwide
collaboration with Roche and Genentech, a member of the Roche
Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in
Phase 1/2a development for the treatment of acute spinal cord
injuries; (iii) VAC2, a dendritic cell therapy produced from
Lineage’s VAC technology platform for immuno-oncology and
infectious disease, currently in Phase 1 clinical development for
the treatment of non-small cell lung cancer (iv) ANP1, an auditory
neuronal progenitor cell therapy for the potential treatment of
auditory neuropathy, and (v) PNC1, a photoreceptor neural cell
therapy for the treatment of vision loss due to photoreceptor
dysfunction or damage. For more information, please visit
www.lineagecell.com or follow the company on Twitter
@LineageCell.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220426005359/en/
Lineage Cell Therapeutics, Inc. IR Ioana C. Hone
(ir@lineagecell.com) (442) 287-8963 Solebury Trout IR Mike
Biega (Mbiega@soleburytrout.com) (617) 221-9660 |Russo Partners
– Media Relations Nic Johnson or David Schull
Nic.johnson@russopartnersllc.com David.schull@russopartnersllc.com
(212) 845-4242
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Sep 2023 to Sep 2024